Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.5K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

12.0K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
12.0K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

7.5K
Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.5K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

2.3K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.3K
Experimental RNAi02:15

Experimental RNAi

6.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibition.

Molecular therapy. Oncology·2026
Same author

Differential immune infiltrates in histomorphologic Wilms tumor regions identify prognostic macrophages.

Molecular therapy. Oncology·2026
Same author

Modelling EWS::FLI1 protein fluctuations reveal determinants of tumor plasticity in Ewing sarcoma.

EMBO molecular medicine·2026
Same author

Advancing Preclinical Biology for Ewing Sarcoma: An International Effort.

Molecular cancer therapeutics·2025
Same author

Advancing Preclinical Biology for Ewing Sarcoma: An International Effort.

Molecular cancer therapeutics·2025
Same author

YAP1 is a key regulator of EWS::FLI1-dependent malignant transformation upon IGF-1-mediated reprogramming of bone mesenchymal stem cells.

Cell reports·2025
Same journal

RETRACTED: Bakshi et al. Crocin Inhibits Angiogenesis and Metastasis in Colon Cancer via TNF-α/NF-kB/VEGF Pathways. <i>Cells</i> 2022, <i>11</i>, 1502.

Cells·2026
Same journal

Correction: Verde et al. Molecular Mechanisms of Protein Aggregation in ALS-FTD: Focus on TDP-43 and Cellular Protective Responses. <i>Cells</i> 2025, <i>14</i>, 680.

Cells·2026
Same journal

Inflammation in Cardiomyopathies: Cellular Mechanisms Across Cardiac Phenotype.

Cells·2026
Same journal

IL-4/IL-13-Driven Dysregulation of Epidermal Lipid Metabolism in Atopic Dermatitis: An Immunometabolic Link Between Type 2 Inflammation and Barrier Dysfunction.

Cells·2026
Same journal

Activity of DNA- and RNA-Guided Prokaryotic Argonautes in Human Mitochondria.

Cells·2026
Same journal

Placental Pathophysiology in Maternal Psychoactive Substance Use: Biological, Clinical, and Forensic Perspectives.

Cells·2026
See all related articles

Related Experiment Video

Updated: Sep 26, 2025

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

2.9K

Zooming in on Long Non-Coding RNAs in Ewing Sarcoma Pathogenesis.

Dave N T Aryee1,2, Valerie Fock1, Utkarsh Kapoor1

  • 1St. Anna Children's Cancer Research Institute, 1090 Vienna, Austria.

Cells
|April 23, 2022
PubMed
Summary
This summary is machine-generated.

Long non-coding RNAs (lncRNAs) are key players in Ewing sarcoma (ES) development and progression. This review highlights lncRNAs as potential biomarkers and therapeutic targets for this rare bone cancer.

Keywords:
Ewing sarcomabiomarkerscompeting endogenous (ce) RNAlong non-coding RNAsregulatory RNAtherapeutic targets

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.6K

Related Experiment Videos

Last Updated: Sep 26, 2025

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

2.9K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Ewing sarcoma (ES) is an aggressive bone and soft tissue cancer primarily affecting children and young adults.
  • The EWS-FLI1 fusion protein drives sarcomagenesis in about 90% of ES cases.
  • Current treatments offer limited success for metastatic or relapsed disease, necessitating research into treatment resistance.

Purpose of the Study:

  • To comprehensively review long non-coding RNAs (lncRNAs) implicated in Ewing sarcoma (ES).
  • To explore the potential of lncRNAs as biomarkers and therapeutic targets for ES.
  • To address the knowledge gap regarding ES-specific lncRNAs.

Main Methods:

  • Literature review of scientific publications on lncRNAs and Ewing sarcoma.
  • Analysis of current research on epigenetic mechanisms in ES.
  • Synthesis of findings on lncRNA functions in cancer development, metastasis, and drug resistance.

Main Results:

  • lncRNAs are dysregulated in various diseases, including cancer, and play roles in tumorigenesis.
  • Specific lncRNAs are implicated in ES cell proliferation, migration, and invasion.
  • ES genomes are relatively stable, making epigenetic factors like lncRNAs crucial for disease progression.

Conclusions:

  • lncRNAs represent promising biomarkers for ES diagnosis and prognosis.
  • Targeting lncRNAs offers a potential therapeutic strategy for ES, particularly for resistant or metastatic cases.
  • This review provides a focused overview of ES-associated lncRNAs, identifying them as critical targets for future research and clinical application.